Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells ONCOTARGET Li, Q., Yin, L., Jones, L. W., Chu, G. C., Wu, J. B., Huang, J., Li, Q., You, S., Kim, J., Lu, Y., Mrdenovic, S., Wang, R., Freeman, M. R., Garraway, I., Lewis, M. S., Chung, L. W., Zhau, H. E. 2016; 7 (51): 84645-84657


Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKL-independent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular matrices, but not receptor activator NF-?B ligand (RANKL) signaling networks in prostate cancer cells. Our results suggest new inhibitors targeting RANKL-independent pathways should be developed for the treatment of prostate cancer bone and soft tissue metastases.

View details for DOI 10.18632/oncotarget.13175

View details for Web of Science ID 000391353200069

View details for PubMedID 27835867